Patent · US Active

Engineered nucleic acid-targeting nucleic acids

US9816093B1 · kind B1 · utility

56Cited by

14References

20Claims

0Family size

Assignee

Caribou Biosciences, Inc. · US

Inventors

Paul Daniel Donohoue · Berkeley, US
Andrew Paul May · South San Francisco, US

Key dates

Filing date	Dec 6, 2016
Grant date	Nov 14, 2017
Priority date	—
Expiry date	Dec 6, 2036

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC12N2320/33
WIPO fieldBiotechnology
WIPO sectorChemistry

Abstract

The present disclosure provides engineered Class 2 CRISPR-Cas-associated discontinuous first-stem nucleic-acid targeting nucleic acids, nucleoprotein complexes comprising these nucleic acids, and compositions thereof. Nucleic acid sequences encoding the Class 2 CRISPR-Cas-associated discontinuous first-stem nucleic-acid targeting nucleic acids, as well as expression cassettes, vectors and cells comprising such nucleic acid sequences, are described. Also, methods are disclosed for making and using the Class 2 CRISPR-Cas-associated discontinuous first-stem nucleic-acid targeting nucleic acids, nucleoprotein complexes comprising such nucleic acids, and compositions thereof.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.